Evaluating 3L Treatment Landscape Evolution
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Stay updated with breaking news from Third Line Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.